AIM
RNAM

Aigen Investment Management’s Avidity Biosciences RNAM Stock Holding History

Aigen Investment Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,270
Closed -$473K – 991
2024
Q4 		$473K Buy
+16,270
New +$680K 0.08% 345
2023
Q4 		– Sell
-11,177
Closed -$71.3K – 1036
2023
Q3 		$71.3K Buy
+11,177
New +$96.3K 0.01% 764

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aigen Investment Management's RNAM Position: Q1 2025 in Review

Aigen Investment Management sold out of Avidity Biosciences (RNAM) in Q1 2025, closing a stake of 16,270 shares — an estimated $473K sold.

Aigen Investment Management first reported a position in RNAM in Q3 2023 and held it in 2 quarters. The position peaked at $473K in Q4 2024. 220 funds tracked by Wall St. Rank hold RNAM as of Q1 2025.

  • Aigen Investment Management reported no remaining Avidity Biosciences position as of Q1 2025 after selling out during the quarter.
  • Aigen Investment Management sold 16,270 Avidity Biosciences shares in Q1 2025, an estimated $473K.
  • Aigen Investment Management first reported a position in Avidity Biosciences in Q3 2023 and held it in 2 quarters.
  • Aigen Investment Management's Avidity Biosciences position peaked at $473K in Q4 2024.
  • 220 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2025.

Based on Aigen Investment Management's 13F filing for Q1 2025, filed 12 May 2025.